ID   ACVL1_HUMAN             Reviewed;         503 AA.
AC   P37023; A6NGA8;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   15-DEC-1998, sequence version 2.
DT   10-MAY-2017, entry version 190.
DE   RecName: Full=Serine/threonine-protein kinase receptor R3;
DE            Short=SKR3;
DE            EC=2.7.11.30;
DE   AltName: Full=Activin receptor-like kinase 1;
DE            Short=ALK-1;
DE   AltName: Full=TGF-B superfamily receptor type I;
DE            Short=TSR-I;
DE   Flags: Precursor;
GN   Name=ACVRL1; Synonyms=ACVRLK1, ALK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   PubMed=8397373;
RA   ten Dijke P., Ichijo H., Franzen P., Schulz P., Saras J.,
RA   Toyoshima H., Heldin C.-H., Miyazono K.;
RT   "Activin receptor-like kinases: a novel subclass of cell-surface
RT   receptors with predicted serine/threonine kinase activity.";
RL   Oncogene 8:2879-2887(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8242742; DOI=10.1016/0092-8674(93)90488-C;
RA   Attisano L., Carcamo J., Ventura F., Weis F.M., Massague J.,
RA   Wrana J.L.;
RT   "Identification of human activin and TGF beta type I receptors that
RT   form heteromeric kinase complexes with type II receptors.";
RL   Cell 75:671-680(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS HHT2 CYS-50; GLN-67;
RP   ILE-333; TRP-374 AND THR-424.
RX   PubMed=9245985; DOI=10.1086/513903;
RA   Berg J.N., Gallione C.J., Stenzel T.T., Johnson D.W., Allen W.P.,
RA   Schwartz C.E., Jackson C.E., Porteous M.E.M., Marchuk D.A.;
RT   "The activin receptor-like kinase 1 gene: genomic structure and
RT   mutations in hereditary hemorrhagic telangiectasia type 2.";
RL   Am. J. Hum. Genet. 61:60-67(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   STRUCTURE BY NMR OF 19-118, FUNCTION AS BMP9 RECEPTOR, DISULFIDE
RP   BONDS, AND MUTAGENESIS OF 74-ARG--LEU-76.
RX   PubMed=22799562; DOI=10.1021/bi300942x;
RA   Mahlawat P., Ilangovan U., Biswas T., Sun L.Z., Hinck A.P.;
RT   "Structure of the Alk1 extracellular domain and characterization of
RT   its bone morphogenetic protein (BMP) binding properties.";
RL   Biochemistry 51:6328-6341(2012).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (3.36 ANGSTROMS) OF 22-118 IN COMPLEX WITH BMP9
RP   AND ACVR2B, FUNCTION AS BMP9 AND BMP10 RECEPTOR, AND DISULFIDE BONDS.
RX   PubMed=22718755; DOI=10.1074/jbc.M112.377960;
RA   Townson S.A., Martinez-Hackert E., Greppi C., Lowden P., Sako D.,
RA   Liu J., Ucran J.A., Liharska K., Underwood K.W., Seehra J., Kumar R.,
RA   Grinberg A.V.;
RT   "Specificity and structure of a high affinity activin receptor-like
RT   kinase 1 (ALK1) signaling complex.";
RL   J. Biol. Chem. 287:27313-27325(2012).
RN   [9]
RP   VARIANTS HHT2 SER-232 DEL; ARG-376 AND GLN-411.
RX   PubMed=8640225; DOI=10.1038/ng0696-189;
RA   Johnson D.W., Berg J.N., Baldwin M.A., Gallione C.J., Marondel I.,
RA   Yoon S.-J., Stenzel T.T., Speer M., Pericak-Vance M.A., Diamond A.,
RA   Guttmacher A.E., Jackson C.E., Attisano L., Kucherlapati R.,
RA   Porteous M.E.M., Marchuk D.A.;
RT   "Mutations in the activin receptor-like kinase 1 gene in hereditary
RT   haemorrhagic telangiectasia type 2.";
RL   Nat. Genet. 13:189-194(1996).
RN   [10]
RP   VARIANTS HHT2 TYR-51; TRP-77 AND ASP-96.
RX   PubMed=10694922;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:2<137::AID-HUMU15>3.0.CO;2-M;
RA   Klaus D.J., Gallione C.J., Anthony K., Yeh E.Y., Yu J., Lux A.,
RA   Johnson D.W., Marchuk D.A.;
RT   "Novel missense and frameshift mutations in the activin receptor-like
RT   kinase-1 gene in hereditary hemorrhagic telangiectasia.";
RL   Hum. Mutat. 12:137-137(1998).
RN   [11]
RP   VARIANTS HHT2 GLY-48-49-ALA DELINS EP; CYS-50; SER-232 DEL; ILE-333;
RP   TYR-344 AND ASP-407.
RX   PubMed=10767348; DOI=10.1093/hmg/9.8.1227;
RA   Abdalla S.A., Pece-Barbara N., Vera S., Tapia E., Paez E.,
RA   Bernabeu C., Letarte M.;
RT   "Analysis of ALK-1 and endoglin in newborns from families with
RT   hereditary hemorrhagic telangiectasia type 2.";
RL   Hum. Mol. Genet. 9:1227-1237(2000).
RN   [12]
RP   VARIANTS HHT2 TRP-374 AND ASN-398.
RX   PubMed=11170071;
RX   DOI=10.1002/1096-8628(20010201)98:4<298::AID-AJMG1093>3.0.CO;2-K;
RA   Kjeldsen A.D., Brusgaard K., Poulsen L., Kruse T., Rasmussen K.,
RA   Green A., Vase P.;
RT   "Mutations in the ALK-1 gene and the phenotype of hereditary
RT   hemorrhagic telangiectasia in two large Danish families.";
RL   Am. J. Med. Genet. 98:298-302(2001).
RN   [13]
RP   VARIANTS HHT2 ASP-254 DEL; TRP-411 AND TRP-484.
RX   PubMed=11484689; DOI=10.1056/NEJM200108023450503;
RA   Trembath R.C., Thomson J.R., Machado R.D., Morgan N.V., Atkinson C.,
RA   Winship I., Simonneau G., Galie N., Loyd J.E., Humbert M.,
RA   Nichols W.C., Berg J., Manes A., McGaughran J., Pauciulo M.,
RA   Wheeler L., Morrell N.W.;
RT   "Clinical and molecular genetic features of pulmonary hypertension in
RT   patients with hereditary hemorrhagic telangiectasia.";
RL   N. Engl. J. Med. 345:325-334(2001).
RN   [14]
RP   VARIANTS HHT2 ALA-179; ASP-211; TYR-344; TRP-374; GLN-374; SER-399;
RP   GLN-411 AND THR-487, AND CHARACTERIZATION OF VARIANTS HHT2 CYS-50;
RP   GLN-67; TRP-77; ALA-179; ASP-211; SER-232 DEL; ASP-254 DEL; ILE-333;
RP   TYR-344; GLN-374; LEU-378; GLN-411 AND THR-487.
RX   PubMed=14684682; DOI=10.1136/jmg.40.12.865;
RA   Harrison R.E., Flanagan J.A., Sankelo M., Abdalla S.A., Rowell J.,
RA   Machado R.D., Elliott C.G., Robbins I.M., Olschewski H.,
RA   McLaughlin V., Gruenig E., Kermeen F., Halme M.,
RA   Raeisaenen-Sokolowski A., Laitinen T., Morrell N.W., Trembath R.C.;
RT   "Molecular and functional analysis identifies ALK-1 as the predominant
RT   cause of pulmonary hypertension related to hereditary haemorrhagic
RT   telangiectasia.";
RL   J. Med. Genet. 40:865-871(2003).
RN   [15]
RP   ERRATUM.
RA   Harrison R.E., Flanagan J.A., Sankelo M., Abdalla S.A., Rowell J.,
RA   Machado R.D., Elliott C.G., Robbins I.M., Olschewski H.,
RA   McLaughlin V., Gruenig E., Kermeen F., Halme M.,
RA   Raeisaenen-Sokolowski A., Laitinen T., Morrell N.W., Trembath R.C.;
RL   J. Med. Genet. 41:576-576(2004).
RN   [16]
RP   VARIANTS HHT2 ARG-48; LYS-215; ARG-223; ARG-229; SER-233 DEL; PHE-285;
RP   PRO-306; TYR-314; PRO-337; PRO-347; GLN-374; VAL-376; LYS-379;
RP   GLY-397; TRP-411; PRO-411; GLN-411; LEU-425; LEU-479; VAL-482 AND
RP   TRP-484.
RX   PubMed=15024723; DOI=10.1002/humu.20017;
RG   French Rendu-Osler network;
RA   Lesca G., Plauchu H., Coulet F., Lefebvre S., Plessis G., Odent S.,
RA   Riviere S., Leheup B., Goizet C., Carette M.-F., Cordier J.-F.,
RA   Pinson S., Soubrier F., Calender A., Giraud S.;
RT   "Molecular screening of ALK1/ACVRL1 and ENG genes in hereditary
RT   hemorrhagic telangiectasia in France.";
RL   Hum. Mutat. 23:289-299(2004).
RN   [17]
RP   VARIANTS HHT2 TRP-67; TRP-374; LYS-379; ASP-407; TRP-411; VAL-425 AND
RP   PHE-425 DEL.
RX   PubMed=15712270; DOI=10.1002/humu.9311;
RA   Kuehl H.K.A., Caselitz M., Hasenkamp S., Wagner S., El-Harith E.-H.A.,
RA   Manns M.P., Stuhrmann M.;
RT   "Hepatic manifestation is associated with ALK1 in hereditary
RT   hemorrhagic telangiectasia: identification of five novel ALK1 and one
RT   novel ENG mutations.";
RL   Hum. Mutat. 25:320-320(2005).
RN   [18]
RP   VARIANT SER-30, AND VARIANTS HHT2 TYR-34; ALA-52; ILE-197; ASP-219;
RP   LYS-237; LEU-260; PRO-289; ARG-344; CYS-426 AND ARG-433.
RX   PubMed=16752392; DOI=10.1002/humu.20342;
RA   Bossler A.D., Richards J., George C., Godmilow L., Ganguly A.;
RT   "Novel mutations in ENG and ACVRL1 identified in a series of 200
RT   individuals undergoing clinical genetic testing for hereditary
RT   hemorrhagic telangiectasia (HHT): correlation of genotype with
RT   phenotype.";
RL   Hum. Mutat. 27:667-675(2006).
RN   [19]
RP   VARIANTS HHT2 GLY-50; PRO-66; ARG-69; TYR-176; LEU-233; PRO-265;
RP   PRO-403 AND SER-416.
RX   PubMed=16525724;
RA   Argyriou L., Twelkemeyer S., Panchulidze I., Wehner L.E., Teske U.,
RA   Engel W., Nayernia K.;
RT   "Novel mutations in the ENG and ACVRL1 genes causing hereditary
RT   hemorrhagic teleangiectasia.";
RL   Int. J. Mol. Med. 17:655-659(2006).
RN   [20]
RP   VARIANTS CYS-38; PRO-138; LYS-277; PRO-342; THR-400 AND GLU-486, AND
RP   VARIANTS HHT2 SER-96; GLY-217; GLU-226; ARG-280; ARG-294; GLN-328;
RP   HIS-335; ASP-347; SER-378; ARG-424; SER-449 AND PRO-479.
RX   PubMed=20414677; DOI=10.1007/s00439-010-0825-4;
RA   Richards-Yutz J., Grant K., Chao E.C., Walther S.E., Ganguly A.;
RT   "Update on molecular diagnosis of hereditary hemorrhagic
RT   telangiectasia.";
RL   Hum. Genet. 128:61-77(2010).
RN   [21]
RP   VARIANTS HHT2 GLY-41; TYR-41; GLY-46; PRO-47; TYR-66; PHE-77; ASP-211;
RP   SER-211; VAL-245; PRO-306; VAL-313; TYR-314; SER-378; ASP-379;
RP   LYS-379; GLY-404; TRP-411; MET-441 AND TYR-443, VARIANTS ASP-111 AND
RP   PHE-417, CHARACTERIZATION OF VARIANTS HHT2 GLY-41; TYR-41; GLY-46;
RP   PRO-47; TYR-66; PHE-77; ASP-211; SER-211; VAL-245; PRO-306; VAL-313;
RP   TYR-314; SER-378; ASP-379; LYS-379; GLY-404; TRP-411; MET-441 AND
RP   TYR-443, CHARACTERIZATION OF VARIANTS ASP-111 AND PHE-417, FUNCTION,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=26176610; DOI=10.1371/journal.pone.0132111;
RA   Alaa El Din F., Patri S., Thoreau V., Rodriguez-Ballesteros M.,
RA   Hamade E., Bailly S., Gilbert-Dussardier B., Abou Merhi R., Kitzis A.;
RT   "Functional and splicing defect analysis of 23 ACVRL1 mutations in a
RT   cohort of patients affected by hereditary hemorrhagic
RT   telangiectasia.";
RL   PLoS ONE 10:E0132111-E0132111(2015).
CC   -!- FUNCTION: Type I receptor for TGF-beta family ligands BMP9/GDF2
CC       and BMP10 and important regulator of normal blood vessel
CC       development. On ligand binding, forms a receptor complex
CC       consisting of two type II and two type I transmembrane
CC       serine/threonine kinases. Type II receptors phosphorylate and
CC       activate type I receptors which autophosphorylate, then bind and
CC       activate SMAD transcriptional regulators. May bind activin as
CC       well. {ECO:0000269|PubMed:22718755, ECO:0000269|PubMed:22799562,
CC       ECO:0000269|PubMed:26176610}.
CC   -!- CATALYTIC ACTIVITY: ATP + [receptor-protein] = ADP + [receptor-
CC       protein] phosphate.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:26176610};
CC       Single-pass type I membrane protein {ECO:0000255}.
CC   -!- DISEASE: Telangiectasia, hereditary hemorrhagic, 2 (HHT2)
CC       [MIM:600376]: A multisystemic vascular dysplasia leading to
CC       dilation of permanent blood vessels and arteriovenous
CC       malformations of skin, mucosa, and viscera. The disease is
CC       characterized by recurrent epistaxis and gastro-intestinal
CC       hemorrhage. Visceral involvement includes arteriovenous
CC       malformations of the lung, liver, and brain.
CC       {ECO:0000269|PubMed:10694922, ECO:0000269|PubMed:10767348,
CC       ECO:0000269|PubMed:11170071, ECO:0000269|PubMed:11484689,
CC       ECO:0000269|PubMed:14684682, ECO:0000269|PubMed:15024723,
CC       ECO:0000269|PubMed:15712270, ECO:0000269|PubMed:16525724,
CC       ECO:0000269|PubMed:16752392, ECO:0000269|PubMed:20414677,
CC       ECO:0000269|PubMed:26176610, ECO:0000269|PubMed:8640225,
CC       ECO:0000269|PubMed:9245985}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. TGFB receptor subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Hereditary Hemorrhagic Telangiectasia and ENG;
CC       URL="http://arup.utah.edu/database/ACVRL1/ACVRL1_welcome.php";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z22533; CAA80255.1; -; mRNA.
DR   EMBL; L17075; AAA16160.1; -; mRNA.
DR   EMBL; U77713; AAB61900.1; -; Genomic_DNA.
DR   EMBL; U77707; AAB61900.1; JOINED; Genomic_DNA.
DR   EMBL; U77708; AAB61900.1; JOINED; Genomic_DNA.
DR   EMBL; U77709; AAB61900.1; JOINED; Genomic_DNA.
DR   EMBL; U77710; AAB61900.1; JOINED; Genomic_DNA.
DR   EMBL; U77711; AAB61900.1; JOINED; Genomic_DNA.
DR   EMBL; U77712; AAB61900.1; JOINED; Genomic_DNA.
DR   EMBL; AC025259; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471111; EAW58213.1; -; Genomic_DNA.
DR   EMBL; BC042637; AAH42637.1; -; mRNA.
DR   CCDS; CCDS31804.1; -.
DR   PIR; A49431; A49431.
DR   RefSeq; NP_000011.2; NM_000020.2.
DR   RefSeq; NP_001070869.1; NM_001077401.1.
DR   RefSeq; XP_005269292.1; XM_005269235.2.
DR   UniGene; Hs.591026; -.
DR   PDB; 2LCR; NMR; -; A=22-118.
DR   PDB; 3MY0; X-ray; 2.65 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X=195-497.
DR   PDB; 4FAO; X-ray; 3.36 A; C/D/I/J/O/P/U/V/c/d/i/j=22-118.
DR   PDBsum; 2LCR; -.
DR   PDBsum; 3MY0; -.
DR   PDBsum; 4FAO; -.
DR   ProteinModelPortal; P37023; -.
DR   SMR; P37023; -.
DR   BioGrid; 106609; 18.
DR   DIP; DIP-5938N; -.
DR   IntAct; P37023; 1.
DR   STRING; 9606.ENSP00000373574; -.
DR   BindingDB; P37023; -.
DR   ChEMBL; CHEMBL5311; -.
DR   DrugBank; DB00171; Adenosine triphosphate.
DR   GuidetoPHARMACOLOGY; 1784; -.
DR   iPTMnet; P37023; -.
DR   PhosphoSitePlus; P37023; -.
DR   BioMuta; ACVRL1; -.
DR   DMDM; 3915750; -.
DR   EPD; P37023; -.
DR   PaxDb; P37023; -.
DR   PeptideAtlas; P37023; -.
DR   PRIDE; P37023; -.
DR   DNASU; 94; -.
DR   Ensembl; ENST00000388922; ENSP00000373574; ENSG00000139567.
DR   GeneID; 94; -.
DR   KEGG; hsa:94; -.
DR   UCSC; uc001rzj.4; human.
DR   CTD; 94; -.
DR   DisGeNET; 94; -.
DR   GeneCards; ACVRL1; -.
DR   GeneReviews; ACVRL1; -.
DR   HGNC; HGNC:175; ACVRL1.
DR   HPA; HPA007041; -.
DR   MalaCards; ACVRL1; -.
DR   MIM; 600376; phenotype.
DR   MIM; 601284; gene.
DR   neXtProt; NX_P37023; -.
DR   OpenTargets; ENSG00000139567; -.
DR   Orphanet; 774; Hereditary hemorrhagic telangiectasia.
DR   Orphanet; 275777; Heritable pulmonary arterial hypertension.
DR   PharmGKB; PA24496; -.
DR   eggNOG; KOG2052; Eukaryota.
DR   eggNOG; ENOG410XQT0; LUCA.
DR   GeneTree; ENSGT00760000118876; -.
DR   HOGENOM; HOG000230587; -.
DR   HOVERGEN; HBG054502; -.
DR   InParanoid; P37023; -.
DR   KO; K13594; -.
DR   PhylomeDB; P37023; -.
DR   TreeFam; TF314724; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   BRENDA; 2.7.11.30; 2681.
DR   SignaLink; P37023; -.
DR   SIGNOR; P37023; -.
DR   ChiTaRS; ACVRL1; human.
DR   GeneWiki; ACVRL1; -.
DR   GenomeRNAi; 94; -.
DR   PRO; PR:P37023; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000139567; -.
DR   CleanEx; HS_ACVRL1; -.
DR   ExpressionAtlas; P37023; baseline and differential.
DR   Genevisible; P37023; HS.
DR   GO; GO:0009986; C:cell surface; IDA:MGI.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0048185; F:activin binding; IDA:UniProtKB.
DR   GO; GO:0016361; F:activin receptor activity, type I; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IDA:HGNC.
DR   GO; GO:0098821; F:BMP receptor activity; IMP:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0019901; F:protein kinase binding; IPI:BHF-UCL.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:HGNC.
DR   GO; GO:0004702; F:signal transducer, downstream of receptor, with serine/threonine kinase activity; IEA:Ensembl.
DR   GO; GO:0046332; F:SMAD binding; IDA:HGNC.
DR   GO; GO:0050431; F:transforming growth factor beta binding; IPI:UniProtKB.
DR   GO; GO:0005025; F:transforming growth factor beta receptor activity, type I; IEA:Ensembl.
DR   GO; GO:0005024; F:transforming growth factor beta-activated receptor activity; IDA:MGI.
DR   GO; GO:0004675; F:transmembrane receptor protein serine/threonine kinase activity; NAS:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; IMP:HGNC.
DR   GO; GO:0060840; P:artery development; ISS:BHF-UCL.
DR   GO; GO:0008015; P:blood circulation; IMP:HGNC.
DR   GO; GO:0002043; P:blood vessel endothelial cell proliferation involved in sprouting angiogenesis; TAS:DFLAT.
DR   GO; GO:0001955; P:blood vessel maturation; TAS:DFLAT.
DR   GO; GO:0001974; P:blood vessel remodeling; ISS:BHF-UCL.
DR   GO; GO:0030509; P:BMP signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0071773; P:cellular response to BMP stimulus; IMP:BHF-UCL.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IDA:BHF-UCL.
DR   GO; GO:0035912; P:dorsal aorta morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003203; P:endocardial cushion morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0061154; P:endothelial tube morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0001946; P:lymphangiogenesis; ISS:BHF-UCL.
DR   GO; GO:0060836; P:lymphatic endothelial cell differentiation; IMP:BHF-UCL.
DR   GO; GO:0043537; P:negative regulation of blood vessel endothelial cell migration; IMP:BHF-UCL.
DR   GO; GO:0007162; P:negative regulation of cell adhesion; IMP:HGNC.
DR   GO; GO:0030308; P:negative regulation of cell growth; IDA:BHF-UCL.
DR   GO; GO:0030336; P:negative regulation of cell migration; IMP:HGNC.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IMP:HGNC.
DR   GO; GO:2000279; P:negative regulation of DNA biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0045602; P:negative regulation of endothelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0010596; P:negative regulation of endothelial cell migration; IDA:BHF-UCL.
DR   GO; GO:0001937; P:negative regulation of endothelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0051895; P:negative regulation of focal adhesion assembly; IMP:HGNC.
DR   GO; GO:0010629; P:negative regulation of gene expression; ISS:BHF-UCL.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0030513; P:positive regulation of BMP signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0032332; P:positive regulation of chondrocyte differentiation; TAS:BHF-UCL.
DR   GO; GO:0045603; P:positive regulation of endothelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; IMP:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:HGNC.
DR   GO; GO:0051291; P:protein heterooligomerization; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:HGNC.
DR   GO; GO:0008217; P:regulation of blood pressure; IMP:HGNC.
DR   GO; GO:0043535; P:regulation of blood vessel endothelial cell migration; TAS:DFLAT.
DR   GO; GO:0006275; P:regulation of DNA replication; TAS:DFLAT.
DR   GO; GO:0001936; P:regulation of endothelial cell proliferation; TAS:DFLAT.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IMP:HGNC.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0061298; P:retina vasculature development in camera-type eye; ISS:BHF-UCL.
DR   GO; GO:0007165; P:signal transduction; IDA:HGNC.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:HGNC.
DR   GO; GO:0060841; P:venous blood vessel development; ISS:BHF-UCL.
DR   GO; GO:0035313; P:wound healing, spreading of epidermal cells; IMP:HGNC.
DR   InterPro; IPR003605; GS_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR000333; TGFB_receptor.
DR   PANTHER; PTHR23255; PTHR23255; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF08515; TGF_beta_GS; 1.
DR   PRINTS; PR00653; ACTIVIN2R.
DR   SMART; SM00467; GS; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51256; GS; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Angiogenesis; ATP-binding; Cell membrane;
KW   Complete proteome; Disease mutation; Disulfide bond; Glycoprotein;
KW   Kinase; Magnesium; Manganese; Membrane; Metal-binding;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Serine/threonine-protein kinase; Signal;
KW   Transferase; Transmembrane; Transmembrane helix.
FT   SIGNAL        1     21       {ECO:0000255}.
FT   CHAIN        22    503       Serine/threonine-protein kinase receptor
FT                                R3.
FT                                /FTId=PRO_0000024420.
FT   TOPO_DOM     22    118       Extracellular. {ECO:0000255}.
FT   TRANSMEM    119    141       Helical. {ECO:0000255}.
FT   TOPO_DOM    142    503       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      172    201       GS. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00585}.
FT   DOMAIN      202    492       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     208    216       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION       73     76       Mediates specificity for BMP ligand.
FT   ACT_SITE    330    330       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     229    229       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     155    155       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q61288}.
FT   MOD_RES     160    160       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q61288}.
FT   MOD_RES     161    161       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q61288}.
FT   CARBOHYD     98     98       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     34     51       {ECO:0000244|PDB:2LCR,
FT                                ECO:0000244|PDB:4FAO,
FT                                ECO:0000269|PubMed:22718755,
FT                                ECO:0000269|PubMed:22799562}.
FT   DISULFID     36     41       {ECO:0000244|PDB:2LCR,
FT                                ECO:0000244|PDB:4FAO,
FT                                ECO:0000269|PubMed:22718755,
FT                                ECO:0000269|PubMed:22799562}.
FT   DISULFID     46     69       {ECO:0000244|PDB:2LCR,
FT                                ECO:0000244|PDB:4FAO,
FT                                ECO:0000269|PubMed:22718755,
FT                                ECO:0000269|PubMed:22799562}.
FT   DISULFID     77     89       {ECO:0000244|PDB:2LCR,
FT                                ECO:0000244|PDB:4FAO,
FT                                ECO:0000269|PubMed:22718755,
FT                                ECO:0000269|PubMed:22799562}.
FT   DISULFID     90     95       {ECO:0000244|PDB:2LCR,
FT                                ECO:0000244|PDB:4FAO,
FT                                ECO:0000269|PubMed:22718755,
FT                                ECO:0000269|PubMed:22799562}.
FT   VARIANT      30     30       P -> S (found in a patient with
FT                                hereditary hemorrhagic talagiectasia;
FT                                unknown pathological significance;
FT                                dbSNP:rs149664056).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070308.
FT   VARIANT      34     34       C -> Y (in HHT2).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070309.
FT   VARIANT      38     38       S -> C. {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070310.
FT   VARIANT      41     41       C -> G (in HHT2; loss of receptor
FT                                activity in response to BMP9;
FT                                predominantly retained in the endoplasmic
FT                                reticulum).
FT                                {ECO:0000269|PubMed:26176610}.
FT                                /FTId=VAR_075231.
FT   VARIANT      41     41       C -> Y (in HHT2; loss of receptor
FT                                activity in response to BMP9;
FT                                predominantly retained in the endoplasmic
FT                                reticulum).
FT                                {ECO:0000269|PubMed:26176610}.
FT                                /FTId=VAR_075232.
FT   VARIANT      46     46       C -> G (in HHT2; loss of receptor
FT                                activity in response to BMP9; retained in
FT                                the endoplasmic reticulum).
FT                                {ECO:0000269|PubMed:26176610}.
FT                                /FTId=VAR_075233.
FT   VARIANT      47     47       R -> P (in HHT2; loss of receptor
FT                                activity in response to BMP9; retained in
FT                                the endoplasmic reticulum).
FT                                {ECO:0000269|PubMed:26176610}.
FT                                /FTId=VAR_075234.
FT   VARIANT      48     49       GA -> EP (in HHT2; dbSNP:rs387906392).
FT                                /FTId=VAR_026784.
FT   VARIANT      48     48       G -> R (in HHT2).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026785.
FT   VARIANT      50     50       W -> C (in HHT2; retained in the
FT                                endoplasmic reticulum;
FT                                dbSNP:rs121909285).
FT                                {ECO:0000269|PubMed:10767348,
FT                                ECO:0000269|PubMed:14684682,
FT                                ECO:0000269|PubMed:9245985}.
FT                                /FTId=VAR_006204.
FT   VARIANT      50     50       W -> G (in HHT2).
FT                                {ECO:0000269|PubMed:16525724}.
FT                                /FTId=VAR_070311.
FT   VARIANT      51     51       C -> Y (in HHT2; dbSNP:rs863223409).
FT                                {ECO:0000269|PubMed:10694922}.
FT                                /FTId=VAR_006205.
FT   VARIANT      52     52       T -> A (in HHT2).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070312.
FT   VARIANT      66     66       H -> P (in HHT2).
FT                                {ECO:0000269|PubMed:16525724}.
FT                                /FTId=VAR_070313.
FT   VARIANT      66     66       H -> Y (in HHT2; loss of receptor
FT                                activity in response to BMP9; retained in
FT                                the endoplasmic reticulum).
FT                                {ECO:0000269|PubMed:26176610}.
FT                                /FTId=VAR_075235.
FT   VARIANT      67     67       R -> Q (in HHT2; retained in the
FT                                endoplasmic reticulum;
FT                                dbSNP:rs863223414).
FT                                {ECO:0000269|PubMed:14684682,
FT                                ECO:0000269|PubMed:9245985}.
FT                                /FTId=VAR_006206.
FT   VARIANT      67     67       R -> W (in HHT2).
FT                                {ECO:0000269|PubMed:15712270}.
FT                                /FTId=VAR_026786.
FT   VARIANT      69     69       C -> R (in HHT2).
FT                                {ECO:0000269|PubMed:16525724}.
FT                                /FTId=VAR_070314.
FT   VARIANT      77     77       C -> F (in HHT2; loss of receptor
FT                                activity in response to BMP9; retained in
FT                                the endoplasmic reticulum).
FT                                {ECO:0000269|PubMed:26176610}.
FT                                /FTId=VAR_075236.
FT   VARIANT      77     77       C -> W (in HHT2; retained in the
FT                                endoplasmic reticulum).
FT                                {ECO:0000269|PubMed:10694922,
FT                                ECO:0000269|PubMed:14684682}.
FT                                /FTId=VAR_006207.
FT   VARIANT      96     96       N -> D (in HHT2).
FT                                {ECO:0000269|PubMed:10694922}.
FT                                /FTId=VAR_006208.
FT   VARIANT      96     96       N -> S (in HHT2).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070315.
FT   VARIANT     111    111       E -> D (rare polymorphism; no loss of
FT                                receptor activity in response to BMP9;
FT                                mutant protein is capable of targeting
FT                                the cell surface appropriately).
FT                                {ECO:0000269|PubMed:26176610}.
FT                                /FTId=VAR_075237.
FT   VARIANT     138    138       L -> P. {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070316.
FT   VARIANT     176    176       D -> Y (in HHT2).
FT                                {ECO:0000269|PubMed:16525724}.
FT                                /FTId=VAR_070317.
FT   VARIANT     179    179       D -> A (in HHT2; mutant protein is
FT                                capable of targeting the cell surface
FT                                appropriately; dbSNP:rs753792569).
FT                                {ECO:0000269|PubMed:14684682}.
FT                                /FTId=VAR_026787.
FT   VARIANT     197    197       T -> I (in HHT2).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070318.
FT   VARIANT     211    211       G -> D (in HHT2; loss of receptor
FT                                activity in response to BMP9; retained in
FT                                the endoplasmic reticulum;
FT                                dbSNP:rs28936687).
FT                                {ECO:0000269|PubMed:14684682,
FT                                ECO:0000269|PubMed:26176610}.
FT                                /FTId=VAR_026788.
FT   VARIANT     211    211       G -> S (in HHT2; loss of receptor
FT                                activity in response to BMP9; retained in
FT                                the endoplasmic reticulum).
FT                                {ECO:0000269|PubMed:26176610}.
FT                                /FTId=VAR_075238.
FT   VARIANT     215    215       E -> K (in HHT2; dbSNP:rs754283265).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026789.
FT   VARIANT     217    217       W -> G (in HHT2).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070319.
FT   VARIANT     219    219       G -> D (in HHT2).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070320.
FT   VARIANT     223    223       G -> R (in HHT2).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026790.
FT   VARIANT     226    226       V -> E (in HHT2).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070321.
FT   VARIANT     229    229       K -> R (in HHT2).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026791.
FT   VARIANT     232    232       Missing (in HHT2; mutant protein is
FT                                capable of targeting the cell surface
FT                                appropriately).
FT                                {ECO:0000269|PubMed:10767348,
FT                                ECO:0000269|PubMed:14684682,
FT                                ECO:0000269|PubMed:8640225}.
FT                                /FTId=VAR_006209.
FT   VARIANT     233    233       S -> L (in HHT2; dbSNP:rs762773076).
FT                                {ECO:0000269|PubMed:16525724}.
FT                                /FTId=VAR_070322.
FT   VARIANT     233    233       Missing (in HHT2).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026792.
FT   VARIANT     237    237       Q -> K (in HHT2).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070323.
FT   VARIANT     245    245       I -> N (in dbSNP:rs1804508).
FT                                /FTId=VAR_011717.
FT   VARIANT     245    245       I -> V (in HHT2; no loss of receptor
FT                                activity in response to BMP9; mutant
FT                                protein is capable of targeting the cell
FT                                surface appropriately; affects splicing
FT                                by inducing the creation of a new donor
FT                                splice site and the loss of the 3' end of
FT                                exon 6). {ECO:0000269|PubMed:26176610}.
FT                                /FTId=VAR_075239.
FT   VARIANT     254    254       Missing (in HHT2; retained in the
FT                                endoplasmic reticulum).
FT                                {ECO:0000269|PubMed:11484689,
FT                                ECO:0000269|PubMed:14684682}.
FT                                /FTId=VAR_026793.
FT   VARIANT     260    260       I -> L (in HHT2).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070324.
FT   VARIANT     265    265       T -> P (in HHT2).
FT                                {ECO:0000269|PubMed:16525724}.
FT                                /FTId=VAR_070325.
FT   VARIANT     277    277       T -> K (found in a patient with
FT                                hereditary hemorrhagic talagiectasia;
FT                                unknown pathological significance).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070326.
FT   VARIANT     280    280       H -> R (in HHT2).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070327.
FT   VARIANT     285    285       L -> F (in HHT2).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026794.
FT   VARIANT     289    289       L -> P (in HHT2).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070328.
FT   VARIANT     294    294       L -> R (in HHT2).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070329.
FT   VARIANT     306    306       A -> P (in HHT2; loss of receptor
FT                                activity in response to BMP9; retained in
FT                                the endoplasmic reticulum).
FT                                {ECO:0000269|PubMed:15024723,
FT                                ECO:0000269|PubMed:26176610}.
FT                                /FTId=VAR_026795.
FT   VARIANT     313    313       L -> V (in HHT2; loss of receptor
FT                                activity in response to BMP9;
FT                                predominantly retained in the endoplasmic
FT                                reticulum).
FT                                {ECO:0000269|PubMed:26176610}.
FT                                /FTId=VAR_075240.
FT   VARIANT     314    314       H -> Y (in HHT2; loss of receptor
FT                                activity in response to BMP9; retained in
FT                                the endoplasmic reticulum).
FT                                {ECO:0000269|PubMed:15024723,
FT                                ECO:0000269|PubMed:26176610}.
FT                                /FTId=VAR_026796.
FT   VARIANT     328    328       H -> Q (in HHT2).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070330.
FT   VARIANT     333    333       S -> I (in HHT2; retained in the
FT                                endoplasmic reticulum;
FT                                dbSNP:rs863223413).
FT                                {ECO:0000269|PubMed:10767348,
FT                                ECO:0000269|PubMed:14684682,
FT                                ECO:0000269|PubMed:9245985}.
FT                                /FTId=VAR_006210.
FT   VARIANT     335    335       N -> H (in HHT2).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070331.
FT   VARIANT     337    337       L -> P (in HHT2).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026797.
FT   VARIANT     342    342       L -> P. {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070332.
FT   VARIANT     344    344       C -> R (in HHT2).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070333.
FT   VARIANT     344    344       C -> Y (in HHT2; retained in the
FT                                endoplasmic reticulum; dbSNP:rs28936688).
FT                                {ECO:0000269|PubMed:10767348,
FT                                ECO:0000269|PubMed:14684682}.
FT                                /FTId=VAR_026798.
FT   VARIANT     347    347       A -> D (in HHT2).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070334.
FT   VARIANT     347    347       A -> P (in HHT2).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026799.
FT   VARIANT     374    374       R -> Q (in HHT2; retained in the
FT                                endoplasmic reticulum).
FT                                {ECO:0000269|PubMed:14684682,
FT                                ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026800.
FT   VARIANT     374    374       R -> W (in HHT2; dbSNP:rs28936401).
FT                                {ECO:0000269|PubMed:11170071,
FT                                ECO:0000269|PubMed:14684682,
FT                                ECO:0000269|PubMed:15712270,
FT                                ECO:0000269|PubMed:9245985}.
FT                                /FTId=VAR_006211.
FT   VARIANT     376    376       M -> R (in HHT2; dbSNP:rs28936399).
FT                                {ECO:0000269|PubMed:8640225}.
FT                                /FTId=VAR_006212.
FT   VARIANT     376    376       M -> V (in HHT2).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026801.
FT   VARIANT     378    378       P -> L (in HHT2; retained in the
FT                                endoplasmic reticulum).
FT                                {ECO:0000269|PubMed:14684682}.
FT                                /FTId=VAR_026802.
FT   VARIANT     378    378       P -> S (in HHT2; loss of receptor
FT                                activity in response to BMP9; retained in
FT                                the endoplasmic reticulum).
FT                                {ECO:0000269|PubMed:20414677,
FT                                ECO:0000269|PubMed:26176610}.
FT                                /FTId=VAR_070335.
FT   VARIANT     379    379       E -> D (in HHT2; loss of receptor
FT                                activity in response to BMP9; retained in
FT                                the endoplasmic reticulum).
FT                                {ECO:0000269|PubMed:26176610}.
FT                                /FTId=VAR_075241.
FT   VARIANT     379    379       E -> K (in HHT2; loss of receptor
FT                                activity in response to BMP9; retained in
FT                                the endoplasmic reticulum).
FT                                {ECO:0000269|PubMed:15024723,
FT                                ECO:0000269|PubMed:15712270,
FT                                ECO:0000269|PubMed:26176610}.
FT                                /FTId=VAR_026803.
FT   VARIANT     397    397       D -> G (in HHT2).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026804.
FT   VARIANT     398    398       I -> N (in HHT2; dbSNP:rs28936400).
FT                                {ECO:0000269|PubMed:11170071}.
FT                                /FTId=VAR_026805.
FT   VARIANT     399    399       W -> S (in HHT2; dbSNP:rs28936402).
FT                                {ECO:0000269|PubMed:14684682}.
FT                                /FTId=VAR_026806.
FT   VARIANT     400    400       A -> T (found in a patient with
FT                                hereditary hemorrhagic talagiectasia;
FT                                unknown pathological significance).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070336.
FT   VARIANT     403    403       L -> P (in HHT2).
FT                                {ECO:0000269|PubMed:16525724}.
FT                                /FTId=VAR_070337.
FT   VARIANT     404    404       V -> G (in HHT2; loss of receptor
FT                                activity in response to BMP9;
FT                                predominantly retained in the endoplasmic
FT                                reticulum).
FT                                {ECO:0000269|PubMed:26176610}.
FT                                /FTId=VAR_075242.
FT   VARIANT     407    407       E -> D (in HHT2).
FT                                {ECO:0000269|PubMed:10767348,
FT                                ECO:0000269|PubMed:15712270}.
FT                                /FTId=VAR_026807.
FT   VARIANT     411    411       R -> P (in HHT2; dbSNP:rs121909284).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026808.
FT   VARIANT     411    411       R -> Q (in HHT2; retained in the
FT                                endoplasmic reticulum; dbSNP:rs28936398).
FT                                {ECO:0000269|PubMed:14684682,
FT                                ECO:0000269|PubMed:15024723,
FT                                ECO:0000269|PubMed:8640225}.
FT                                /FTId=VAR_006213.
FT   VARIANT     411    411       R -> W (in HHT2; loss of receptor
FT                                activity in response to BMP9;
FT                                predominantly retained in the endoplasmic
FT                                reticulum; dbSNP:rs121909287).
FT                                {ECO:0000269|PubMed:11484689,
FT                                ECO:0000269|PubMed:15024723,
FT                                ECO:0000269|PubMed:15712270,
FT                                ECO:0000269|PubMed:26176610}.
FT                                /FTId=VAR_026809.
FT   VARIANT     416    416       G -> S (in HHT2).
FT                                {ECO:0000269|PubMed:16525724}.
FT                                /FTId=VAR_070338.
FT   VARIANT     417    417       I -> F (rare polymorphism; no loss of
FT                                receptor activity in response to BMP9;
FT                                mutant protein is capable of targeting
FT                                the cell surface appropriately;
FT                                dbSNP:rs141653630).
FT                                {ECO:0000269|PubMed:26176610}.
FT                                /FTId=VAR_075243.
FT   VARIANT     424    424       P -> R (in HHT2).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070339.
FT   VARIANT     424    424       P -> T (in HHT2).
FT                                {ECO:0000269|PubMed:9245985}.
FT                                /FTId=VAR_006214.
FT   VARIANT     425    425       F -> L (in HHT2).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026810.
FT   VARIANT     425    425       F -> V (in HHT2).
FT                                {ECO:0000269|PubMed:15712270}.
FT                                /FTId=VAR_026811.
FT   VARIANT     425    425       Missing (in HHT2).
FT                                {ECO:0000269|PubMed:15712270}.
FT                                /FTId=VAR_026812.
FT   VARIANT     426    426       Y -> C (in HHT2).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070340.
FT   VARIANT     433    433       P -> R (in HHT2).
FT                                {ECO:0000269|PubMed:16752392}.
FT                                /FTId=VAR_070341.
FT   VARIANT     441    441       V -> M (in HHT2; retained in the
FT                                endoplasmic reticulum).
FT                                {ECO:0000269|PubMed:26176610}.
FT                                /FTId=VAR_075244.
FT   VARIANT     443    443       C -> Y (in HHT2; retained in the
FT                                endoplasmic reticulum).
FT                                {ECO:0000269|PubMed:26176610}.
FT                                /FTId=VAR_075245.
FT   VARIANT     449    449       P -> S (in HHT2).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070342.
FT   VARIANT     479    479       R -> L (in HHT2).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026813.
FT   VARIANT     479    479       R -> P (in HHT2).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070343.
FT   VARIANT     482    482       A -> V (in HHT2; dbSNP:rs139142865).
FT                                {ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026814.
FT   VARIANT     484    484       R -> W (in HHT2; dbSNP:rs121909288).
FT                                {ECO:0000269|PubMed:11484689,
FT                                ECO:0000269|PubMed:15024723}.
FT                                /FTId=VAR_026815.
FT   VARIANT     486    486       K -> E (found in a patient with
FT                                hereditary hemorrhagic talagiectasia;
FT                                unknown pathological significance;
FT                                dbSNP:rs113700354).
FT                                {ECO:0000269|PubMed:20414677}.
FT                                /FTId=VAR_070344.
FT   VARIANT     487    487       K -> T (in HHT2; mutant protein is
FT                                capable of targeting the cell surface
FT                                appropriately).
FT                                {ECO:0000269|PubMed:14684682}.
FT                                /FTId=VAR_026816.
FT   MUTAGEN      74     76       REL->DFQ: Affinity for BMP9 decreased by
FT                                200-fold. {ECO:0000269|PubMed:22799562}.
FT   CONFLICT    172    172       S -> T (in Ref. 1; CAA80255).
FT                                {ECO:0000305}.
FT   HELIX        26     28       {ECO:0000244|PDB:2LCR}.
FT   STRAND       32     35       {ECO:0000244|PDB:4FAO}.
FT   STRAND       42     56       {ECO:0000244|PDB:4FAO}.
FT   STRAND       59     61       {ECO:0000244|PDB:4FAO}.
FT   STRAND       64     68       {ECO:0000244|PDB:4FAO}.
FT   HELIX        74     78       {ECO:0000244|PDB:4FAO}.
FT   STRAND       83     90       {ECO:0000244|PDB:4FAO}.
FT   TURN         93     96       {ECO:0000244|PDB:4FAO}.
FT   HELIX       198    201       {ECO:0000244|PDB:3MY0}.
FT   STRAND      203    211       {ECO:0000244|PDB:3MY0}.
FT   STRAND      214    221       {ECO:0000244|PDB:3MY0}.
FT   STRAND      224    231       {ECO:0000244|PDB:3MY0}.
FT   HELIX       233    235       {ECO:0000244|PDB:3MY0}.
FT   HELIX       236    248       {ECO:0000244|PDB:3MY0}.
FT   STRAND      259    265       {ECO:0000244|PDB:3MY0}.
FT   STRAND      267    269       {ECO:0000244|PDB:3MY0}.
FT   STRAND      272    278       {ECO:0000244|PDB:3MY0}.
FT   HELIX       285    291       {ECO:0000244|PDB:3MY0}.
FT   HELIX       296    314       {ECO:0000244|PDB:3MY0}.
FT   STRAND      325    327       {ECO:0000244|PDB:3MY0}.
FT   STRAND      335    338       {ECO:0000244|PDB:3MY0}.
FT   STRAND      344    346       {ECO:0000244|PDB:3MY0}.
FT   STRAND      353    355       {ECO:0000244|PDB:3MY0}.
FT   STRAND      357    359       {ECO:0000244|PDB:3MY0}.
FT   HELIX       373    375       {ECO:0000244|PDB:3MY0}.
FT   HELIX       378    381       {ECO:0000244|PDB:3MY0}.
FT   HELIX       390    410       {ECO:0000244|PDB:3MY0}.
FT   TURN        424    428       {ECO:0000244|PDB:3MY0}.
FT   HELIX       435    442       {ECO:0000244|PDB:3MY0}.
FT   STRAND      455    459       {ECO:0000244|PDB:3MY0}.
FT   TURN        460    462       {ECO:0000244|PDB:3MY0}.
FT   HELIX       463    469       {ECO:0000244|PDB:3MY0}.
FT   HELIX       476    478       {ECO:0000244|PDB:3MY0}.
FT   HELIX       482    491       {ECO:0000244|PDB:3MY0}.
SQ   SEQUENCE   503 AA;  56124 MW;  074522AA802325DD CRC64;
     MTLGSPRKGL LMLLMALVTQ GDPVKPSRGP LVTCTCESPH CKGPTCRGAW CTVVLVREEG
     RHPQEHRGCG NLHRELCRGR PTEFVNHYCC DSHLCNHNVS LVLEATQPPS EQPGTDGQLA
     LILGPVLALL ALVALGVLGL WHVRRRQEKQ RGLHSELGES SLILKASEQG DSMLGDLLDS
     DCTTGSGSGL PFLVQRTVAR QVALVECVGK GRYGEVWRGL WHGESVAVKI FSSRDEQSWF
     RETEIYNTVL LRHDNILGFI ASDMTSRNSS TQLWLITHYH EHGSLYDFLQ RQTLEPHLAL
     RLAVSAACGL AHLHVEIFGT QGKPAIAHRD FKSRNVLVKS NLQCCIADLG LAVMHSQGSD
     YLDIGNNPRV GTKRYMAPEV LDEQIRTDCF ESYKWTDIWA FGLVLWEIAR RTIVNGIVED
     YRPPFYDVVP NDPSFEDMKK VVCVDQQTPT IPNRLAADPV LSGLAQMMRE CWYPNPSARL
     TALRIKKTLQ KISNSPEKPK VIQ
//
